Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico.
Aphria Inc. (TSX: APH and US OTC: APHQF) today announced that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart. -
As consumer acceptance continues to propel demand to unprecedented levels, companies such as InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) are making waves in the advancement of cannabinoid compounds as a medical solution in pain management and other indications.-
Hi-tech Greenhouse Positions Spectrum Cannabis as European Cannabis Leader & Odense as Major European Medical Cannabis Centre-
Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) today announced that, further to its press releases of November 23, 2017, the Company has completed the acquisitions of Larssen Ltd, a globally leading greenhouse engineering and design consultancy, and that of H2 Biopharma, a late-stage ACMPR applicant based in Quebec.-
Marijuana Company of America (OTC: MCOA) has established a commanding presence in the cannabis and industrial hemp cannabidiol (“CBD”) markets, as well as the related services supply chain, creating an umbrella over a diverse portfolio of cannabis- and hemp-based companies.
SinglePoint (OTC: SING) this morning said it has entered a joint venture relationship with Smart Cannabis Corp. (OTC: SCNA) to license and market Smart Cannabis’ SMART app.
After considering input from 48,951 British Columbians, and submissions from 141 local and Indigenous governments and a range of other interested stakeholders, the Province has announced a number of key decisions related to the anticipated legalization of non-medical cannabis in July 2018.-
Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018.
Aurora Cannabis Inc. ("Aurora") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Radient Technologies Inc. ("Radient) (TSX-V: RTI) today announced that further to the investor rights agreement between both companies, as announced on November 6, 2017, Aurora will make a further investment in Radient for a total of $12 million
Clinically Meaningful Median Reduction in Seizures Compared to Baseline of 48% to 65% Achieved with Continued ZYN002 Treatment in STAR 2 Extension Study. Data Help Clarify Protocol Design for Planned ZYN002 Phase 2 Trial in Epilepsy -
GW Pharmaceuticals plc (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces financial results for the fourth quarter and year-ended 30 September 2017
Following the November 28, 2017 CanniMed Therapeutics Inc. (TSX: CMED) announcement that it has unilaterally adopted a shareholders' rights plan in response to the compelling offer made by Aurora Cannabis Inc. (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) to CanniMed's shareholders, Aurora provides the following initial response.
Maricann Group Inc. (CSE:MARI)(CSE:MARI.CN)(CNSX:MARI)(OTCQB:MRRCF)(FRANKFURT:75M) filed its financial statements for the 3 months ending September 30, 2017, with results that were consistent with expectations.
Abcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) recently released financial results for the three and nine months ended September 30, 2017.
